TrialScientific reports2021

Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack.

Zeling Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.